Clinical Trial Update: Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BIIB033 (Opicinumab) as add-on therapy to existing disease-modifying therapies in relapsing multiple sclerosis; study terminated with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• BIIB033

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2022-04-28